
Sign up to save your podcasts
Or


At the European Society for Medical Oncology Congress 2022, Dr. Matthew Goetz presented interim overall survival results from the MONARCH 3 study showing that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer.
Listen to the podcast to hear Dr. Goetz explain:
By Breastcancer.org4.3
4242 ratings
At the European Society for Medical Oncology Congress 2022, Dr. Matthew Goetz presented interim overall survival results from the MONARCH 3 study showing that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer.
Listen to the podcast to hear Dr. Goetz explain:

21,941 Listeners

1,115 Listeners

2,033 Listeners

1,691 Listeners

2,637 Listeners

3,493 Listeners

9,295 Listeners

53 Listeners

4,489 Listeners

328 Listeners

388 Listeners

20,212 Listeners

1,177 Listeners

120 Listeners

30 Listeners